? IL-38促進(jìn)前列腺癌的發(fā)展

2024年5月，上海交通大學(xué)醫(yī)學(xué)院附屬銅仁醫(yī)院病理科，上海交通大學(xué)醫(yī)學(xué)院附屬銅仁醫(yī)院病理科（1 Department of Pathology, Tongji Hospital, Tongji University, Shanghai, China, 2Department of Pathology, Tongren Hospital, Shanghai Jiaotong University School of Medicine, Shanghai, China）Shisan Bao2 and Kun Tao1,2研究團(tuán)隊(duì)，在《Frontiers in Immunology》上發(fā)表論文：

“IL-38 promotes the development of prostate cancer”

“IL-38促進(jìn)前列腺癌的發(fā)展”

Abstrac：

Introduction: Prostate Cancer (PCa) remains a significant concern in malecancer-related mortality. Tumour development is intricately regulated by the

complex interactions between tumour cells and their microenvironment, makingit essential to determine which is/are key factor(s) that influence the progressionof PCa within the tumour microenvironment.

Materials and methods: The current study utilised histopathology andimmunohistochemistry to determine the expression of IL-38 in PCa and

analysed the correlation between the expression level of IL-38 within PCa and clinical pathological characteristics.

Results: There was a significant increase in IL-38 expression in PCa tissuescompared to adjacent non-PCa tissues (P < 0.0001). In addition, IL-38 expression

was significantly higher in tumour cells with a high proliferation index compared to those with a low value-added index. ROC curve analysis demonstrated that IL-38 has high specificity and sensitivity for the diagnosis of PCa (AUC=0.76).

Moreover, we Probed the cellular source of IL-38 in prostate cancer tissue by immunofluorescence double staining. Additionally, within PCa, the expression of IL-38 was inversely correlated with the expression levels of CD8 and PD-1.

Survival analysis revealed a significantly lower overall survival rate for PCa patients with high IL-38 expression (P=0.0069), and when IL-38 was co-expressed with CD8, the survival rate of the IL-38high/CD8low group was decreased significantly.

Multivariate analysis indicated that the expression level of IL-38 and TNM staging were independent predictors of survival in PCa patients.

Conclusion: These findings suggest that IL-38 plays a crucial role in the development of PCa, and the exploration of the correlation between IL-38 and

various immune factors in the tumour microenvironment further reveals its mechanism of action, making it a potential target for immunotherapy in PCa.

摘要：

簡介:前列腺癌(PCa)仍然是男性癌癥相關(guān)死亡率的一個(gè)重要問題。腫瘤的發(fā)展受到腫瘤細(xì)胞與其微環(huán)境之間復(fù)雜的相互作用的復(fù)雜調(diào)節(jié)，因此確定哪些是影響腫瘤微環(huán)境中PCa進(jìn)展的關(guān)鍵因素至關(guān)重要。

材料與方法:本研究采用組織病理學(xué)和免疫組織化學(xué)方法檢測前列腺癌組織中IL-38的表達(dá)，分析前列腺癌組織中IL-38表達(dá)水平與臨床病理特征的相關(guān)性。

結(jié)果:前列腺癌組織中IL-38的表達(dá)明顯高于癌旁非前列腺癌組織(P < 0.0001)。此外，IL-38在增殖指數(shù)高的腫瘤細(xì)胞中的表達(dá)明顯高于增值指數(shù)低的腫瘤細(xì)胞。ROC曲線分析顯示IL-38診斷PCa具有較高的特異性和敏感性(AUC=0.76)。此外，科研人員利用免疫熒光雙染色法探索前列腺癌組織中IL-38的細(xì)胞來源。此外，在PCa內(nèi)，IL-38的表達(dá)與CD8和PD-1的表達(dá)水平呈負(fù)相關(guān)。生存分析顯示，IL-38高表達(dá)組的總生存率顯著降低(P=0.0069)， IL-38與CD8共表達(dá)組的生存率顯著降低。多因素分析表明，IL-38表達(dá)水平和TNM分期是前列腺癌患者生存的獨(dú)立預(yù)測因子。

結(jié)論:這些發(fā)現(xiàn)提示IL-38在前列腺癌的發(fā)生發(fā)展中起著至關(guān)重要的作用，探索IL-38與腫瘤微環(huán)境中各種免疫因子的相關(guān)性進(jìn)一步揭示其作用機(jī)制，使其成為前列腺癌免疫治療的潛在靶點(diǎn)。

在該研究中， Ausbian進(jìn)口胎牛血清用于封閉。欲了解或購買Ausbian特級(jí)胎牛血清可以聯(lián)系北京締一生物400-166-8600.